Moderna develops a booster vaccine that combines COVID-19 and flu – Photo: REUTERS
According to Reuters news agency, Moderna hopes that gradually it will be able to combine the vaccines it is working on against respiratory syncytial virus (RSV) and other respiratory diseases in the same annual injection.
Moderna CEO Stéphane Bancel said during an investor briefing on the drugs being developed by the company: “We believe there are huge opportunities ahead if the company can could bring to market an annual booster dose that is highly effective against respiratory diseases.”
Moderna is in clinical trials with an RSV vaccine in older adults and has several flu vaccine candidates in development.
The 2-in-1 vaccine that combines the flu vaccine and the COVID-19 vaccine is very positive news. This information helped the stock of Moderna added 6.2% on 9/9.
Earlier, on September 8, Novavax pharmaceutical company of the US also announced that it is conducting a clinical trial to combine a COVID-19 vaccine with an influenza vaccine to evaluate its safety and ability to generate immunity. from human vaccines.
The trial will be conducted in Australia, at 12 study sites, with 640 healthy volunteers aged 50 to 70 years, who either have had COVID-19 previously, or received a COVID-19 vaccine at least 8 weeks prior to the study. rescue.
According to Reuters news agency, participants will be randomly assigned to groups to evaluate various formulas.
They will receive two doses of the combination vaccine against COVID-19 and the influenza vaccine NanoFlu, or will receive an adjuvant and booster vaccine.
The results of this trial are expected to be available in the first half of 2022.
Previously, separate studies in Brazil, the UK, and the US also led to an unexpected result: the flu vaccine helped reduce severe COVID-19 symptoms. However, studies do not recommend replacing the COVID-19 vaccine with the flu vaccine.